Phenotips vs Progeny Clinical: an honest comparison

This page is a head-to-head comparison of Phenotips and Progeny Clinical. Both are well-established platforms, and teams searching "phenotips vs progeny" usually want a plain-English summary of which is the better fit for their service. That is what this page provides. Evagene is briefly introduced at the end as a third option for readers whose requirements include modern AI, REST API, and agentic integration — but this article is genuinely about Phenotips and Progeny first. All product claims are drawn from each vendor's public website and documentation as of April 2026.

Short version. Choose Phenotips if your service is phenotype-first rare disease diagnostics, HPO capture is central to your workflow, you need an enterprise genomic health record platform, and global (or LGBTQIA+-inclusive) deployment matters. Choose Progeny Clinical if your service is primarily cancer genetics, you value a very long operational track record since 1996, and you need mature EHR integration, test ordering, and letter generation. There are overlaps — both do pedigrees, both do risk assessment, both are used by large institutions — but the centre of gravity is different.

How Phenotips and Progeny position themselves

Phenotips (Gene42 / Think Research) describes itself as "the complete Genomic Health Record" — an EHR-integrated solution for collaborative genomic medicine. Its marketing highlights diagnostic yield for rare disease ("up to 30x faster"), a large installed base (100,000+ patient records, 500+ specialists, 60+ countries per its homepage), and HPO-driven phenotype capture paired with automated gene and disease suggestion. The product is certified across GDPR, DSPT, HIPAA, and CE+ contexts, is designed to be LGBTQIA+-inclusive, and is oriented towards genetics institutions, rare disease clinics, cancer genetics services, and research groups. Its Research Team plan is $399/month for 5 users plus $25 per additional user.

Progeny Clinical (Progeny Genetics, owned by Ambry Genetics since 2018) is the grown-up version of a clinical pedigree product that has been in use since 1996. Its installed base is 800+ genetics institutions. It offers cloud and on-premise deployment, integrated cancer risk modelling, EHR integration, test ordering, and letter generation. Its heritage is cancer genetics, and that remains a dominant use case — though the product is general-purpose enough that it is used in rare disease, reproductive genetics, and wider clinical contexts too. Progeny is HIPAA-compliant; pricing is not published on the public site and is obtained via quote. User feedback over the years has identified friction points: moving family members around in a pedigree can be awkward, some of the advanced features are unintuitive, and some customers have reported rising prices over time.

The difference in posture is important. Phenotips presents itself as a modern platform rethinking the clinical genomic record with phenotype at the centre. Progeny presents itself as the trusted, long-running clinical pedigree system that has quietly powered genetics services for three decades and that has evolved with the market.

Feature comparison

The matrix below compares features each vendor publishes. A tick means the capability is publicly advertised; a dash means it is not publicly listed. We include Evagene as a third column for readers considering it alongside the two primary products.

Matrix compiled from publicly available product pages and documentation as of April 2026. "—" indicates the capability is not publicly advertised and does not necessarily mean it is absent.

Phenotype-first vs pedigree-and-cancer-first

This is the single most consequential axis of difference. Phenotips is built around the Human Phenotype Ontology. Its workflow begins with capturing granular phenotype terms against HPO, then ties those observations to candidate genes and diseases via automated suggestion. This is the modern pattern in undiagnosed rare disease diagnostics: the exome or genome is already sequenced, and the question is which variants to prioritise given the patient's observed phenotype. Phenotips excels here.

Progeny Clinical's centre of gravity is the pedigree and cancer risk. Its patient record ties cleanly to family history, to BRCA-style risk calculations, to referral letters, and to test ordering in a cancer genetics context. For services whose most common question is "given this family history, what is this person's risk of a hereditary cancer syndrome, and should we test?", Progeny's workflow is natural.

Neither tool excludes the other's territory. Phenotips can handle cancer families; Progeny can record phenotype observations. But the defaults, the interface affordances, and the mental model each product optimises for are different.

Deployment, EHR integration, and institutional fit

Progeny Clinical supports both cloud and on-premise deployment. For institutions with strong data localisation requirements, no-internet-egress policies, or internal preferences for hosted-on-our-hardware clinical systems, on-premise Progeny remains a real option. Phenotips's public materials emphasise cloud deployment via cloud.phenotips.com; on-premise is not the headline story.

On EHR integration, both vendors advertise integration, and both have customer evidence of integration in large institutional deployments. The specifics — which EHRs, at what depth, through which adapter — are generally opaque on the public sites and get resolved through the procurement conversation. If this matters to you, get it in writing during vendor evaluation.

Progeny Clinical's cancer-genetics workflow includes native letter generation and test ordering. Phenotips does not advertise the same depth in letter generation; its reporting comes from the broader genomic health record.

Certifications, inclusivity, and governance

Phenotips's public materials advertise GDPR, DSPT, HIPAA, and CE+ certification, and it explicitly highlights LGBTQIA+-inclusive design — a pedigree-symbol choice some services prioritise. Its global deployment across 60+ countries is a strong signal that it has passed a wide range of procurement reviews.

Progeny Clinical is HIPAA-compliant; other certification details are available through the vendor. Its 800+ institutions include large US cancer centres and UK/European teaching hospitals, so procurement-bearing reviews are a well-trodden path.

Both products are credible from a governance perspective. Which one an institution prefers often comes down to alignment between the product's advertised certifications and the institution's current procurement checklist.

Pricing and procurement friction

Phenotips publishes a Research Team plan ($399/month for 5 users, +$25/user additional). That is approximately $4,788/year at entry tier for a 5-user team, which is a friendly price point for a research group but is likely not representative of the institutional clinic or hospital tier. Those are priced on application, and Phenotips runs a demo-then-quote motion.

Progeny Clinical does not publish pricing. Procurement is via quote, with pricing that reflects seat count, deployment (cloud or on-prem), feature set, and negotiation. Some user feedback over the years has flagged rising prices; this is anecdotal and may not reflect current pricing for a specific institution, but it is a reminder that long-term cost trajectory is a legitimate procurement topic to ask about.

Progeny offers a free tier via Progeny Cloud — the stripped-down cloud edition targeted at small clinics and new services.

When to choose Phenotips

• Your service is phenotype-driven rare disease diagnostics and HPO capture is central.
• You need a platform that positions itself as a genomic health record, not just a pedigree tool.
• Global deployment, GDPR/DSPT/HIPAA/CE+ certifications, and LGBTQIA+-inclusive design matter for your institution.
• Your phenotype-to-gene suggestion pipeline is the main diagnostic aid you want from the software.
• You are comfortable with partial public pricing and an enterprise procurement motion.

When to choose Progeny Clinical

• Your service is primarily cancer genetics and the mature cancer-risk workflow is your priority.
• You value a 30-year operational track record and an 800+ institution installed base.
• You need on-premise deployment, or the option of it, alongside cloud.
• Native letter generation and test ordering are part of your daily workflow.
• Your institution wants a single vendor-managed EHR integration path without building it yourselves.
• You are willing to do an enterprise procurement motion for a private quote.

A third option to consider: Evagene

Phenotips and Progeny Clinical are both good choices for their respective sweet spots. For services whose requirements overlap with both but whose priorities include modern AI integration, programmatic access, and a low-friction path to get started, Evagene is worth evaluating alongside them.

Evagene is a browser-based clinical pedigree management platform with gesture drawing, a 200+ disease catalogue coded to ICD-10 and OMIM, integrated BayesMendel cancer risk models (BRCAPRO, MMRpro, PancPRO), Mendelian inheritance analysis for AD/AR/XR patterns, karyogram viewing, and consanguinity detection via Wright's coefficient.

Its AI layer is distinctive: Evagene ships AI clinical interpretation using the service's own LLM keys (Anthropic Claude, OpenAI GPT), encrypted at rest with Fernet. No vendor-hosted model sits between your clinical text and the provider you have already contracted. Analysis Templates let a service codify its house style of report writing. The MCP (Model Context Protocol) server exposes 11 pedigree tools to Claude Desktop, Claude Code, and any other MCP-compatible AI agent, so clinicians can ask their AI assistant to read, modify, or analyse a pedigree directly.

On the integration surface, Evagene offers a scoped, rate-limited REST API with keys in the format evg_ followed by 43 characters (SHA-256 hashed at rest), HMAC-SHA256-signed webhooks across eight event types, and an embeddable pedigree viewer (iframe, SVG, or JavaScript snippet). Imports cover GEDCOM 5.5.1, JSON, 23andMe, XEG, and pedigree image OCR. Exports cover PNG, SVG, and PDF across 4 report types.

Evagene is in Alpha and free via waiting list at evagene.com. It does not replace the enterprise depth of Phenotips or the three-decade track record of Progeny Clinical for institutions that need those. It does offer a credible path for services that want modern AI and programmatic capability at the pedigree layer.

Frequently asked questions

Related reading

• Phenotips vs Evagene
• Progeny vs Evagene
• TrakGene vs Phenotips
• FamGenix vs Progeny
• Pedigree drawing software: a practical guide
• All Evagene comparisons